Medical News Today -
14 Oct 2013 11:00
TherapeuticsMD, Inc. (NYSE MKT:TXMD) - Pharmacokinetic study presented in a poster session at The North American Menopause Society 2013 Annual Meeting in Dallas suggests that the first combination 17β-estradiol and progesterone capsule in clinical development may have overcome the well-recognized difficulties of achieving good bioavailability with oral administration of these hormones in combination. In a study of 66 healthy postmenopausal women, bioavailability of TX 12-001-HR, a capsule con...
Share this Article